Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossCommercial · Coverage · Medical Policy · PA · Genetics, Pediatrics, Internal Medicine +1 moreMedium impact

08.00.51l, Enzyme Replacement for the Treatment of Gaucher's Disease

Act
by Dec 31, 2024
Effective date
Jan 1, 2024
Identified
Jun 19, 2026

Summary

Independence Blue Cross removed its designated preferred product requirement for Gaucher's disease enzyme replacement therapy as of January 1, 2024. All three FDA-approved agents (imiglucerase/Cerezyme, taliglucerase alfa/Elelyso, and velaglucerase alfa/VPRIV) are now equally covered without preference, eliminating previous restrictions that favored VPRIV.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

by Dec 31, 2024 · 5 steps
01Billing team and prior authorization staff must update all internal policies, prior authorization templates, and billing system rules to remove any VPRIV preference language or requirement.
02Ensure claims for Cerezyme (J1786), Elelyso (J3060), and VPRIV (J3385) are processed equally without denial or step-therapy based on product selection.
03Remove any billing software logic that defaults to or requires VPRIV.
04Providers should be notified that all three agents are now interchangeable for coverage purposes as long as medical necessity criteria are met.
05Claims previously denied due to non-preferred product selection may be subject to appeals review.

Codes mentioned

J1786J3060J3385E75.22

Original notice

08.00.51l, Enzyme Replacement for the Treatment of Gaucher's Disease
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.023c, Enzyme Replacement for the Treatment of Gaucher's DiseaseLowNo effective date · Medical PolicyMA08.023d, Enzyme Replacement for the Treatment of Gaucher's DiseaseMediumEffective Jan 1, 2026 · Medical Policy08.00.51m, Enzyme Replacement for the Treatment of Gaucher's DiseaseMediumEffective Jan 1, 2026 · Medical PolicyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesPA policy changesGeneticsPediatricsInternal MedicineHematologyCode J1786Code J3060Code J3385Code E75.22

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account